A higher risk of cardiotoxicity with combination BRAF inhibitor/MEK inhibitor therapy is also suggested in a subsequent meta-analysis9 including 5 randomized clinical trials with a total of 2,317 patients with melanoma treated with BRAF inhibitor and MEK inhibitor. This evidence concerns the gene MAP2K7 and melanoma.